Drug Type Antibody fusion proteins |
Synonyms- |
Target |
Action inhibitors, stimulants |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), IFNA2A stimulants(Interferon alpha 2a stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Preclinical | Switzerland | 28 Apr 2025 | |
Neoplasms | Preclinical | Germany | 28 Apr 2025 | |
Neoplasms | Preclinical | Switzerland | 28 Apr 2025 | |
Neoplasms | Preclinical | United Kingdom | 28 Apr 2025 | |
Non-Small Cell Lung Cancer | Preclinical | Switzerland | 28 Apr 2025 |